By Darrin LaVelle, Founder of RENVA Health
Last updated: July 3, 2026
Short answer: research shows that roughly 20 to 40% of the weight lost on GLP-1 medications can be lean muscle rather than fat, particularly without deliberate attention to protein intake and strength training. This isn't unique to GLP-1s — it happens with most significant weight loss — but it's worth understanding and actively managing, especially for older adults.
Most conversations about GLP-1 medications focus on the number on the scale. But not all weight loss is the same — losing fat and losing muscle have very different implications for your health, strength, and metabolism. Here's what the current research shows about lean mass loss on these medications, and what's known to help protect against it.
A 2025 systematic review and network meta-analysis looking at GLP-1 and dual-agonist medications across multiple obesity trials found that while most weight loss was fat, lean tissue accounted for 20–40% of total weight lost, with the exact proportion varying by drug and dose. A separate 2026 scoping review that examined 12 clinical trials of GLP-1 and dual GIP/GLP-1 therapies found a similar pattern, with lean tissue loss reaching up to 40% of total weight reduction in some studies.
It's worth putting this in context: lean mass loss isn't a GLP-1-specific problem. Diet-only weight loss programs typically show 25–35% of lost weight coming from lean tissue too. What differs with GLP-1 medications is mainly the speed and scale of weight loss they can produce — and faster, larger weight loss (especially at 15% or more of body weight) tends to pull a higher share from lean tissue if nothing is done to counteract it.
This is where the research gets more specific and more concerning. Natural age-related muscle loss (sarcopenia) typically progresses slowly — around 1–2% of muscle mass per year after age 50, alongside 1.5–5% strength loss per year. The 2026 scoping review found that lean mass decline in older adults on GLP-1 therapy, over just 6 to 12 months, exceeded these typical age-related rates — meaning the medication can meaningfully accelerate a process that's already a health concern as people age, if nutrition and exercise aren't actively addressed alongside treatment.
When the body is in a calorie deficit — regardless of why — it draws on both fat and muscle tissue for energy. Whether that balance tips more toward fat or more toward muscle depends heavily on two things: how much protein you're eating, and whether your muscles are getting mechanical loading through resistance exercise. Without enough of either, the body has less reason to preserve muscle tissue during a period of reduced energy intake.
GLP-1 medications add a specific wrinkle here: they reduce overall food intake by roughly 16–39% compared to not taking the medication, according to research on appetite and energy intake. That's the intended effect for weight loss, but it also means less overall food volume — which, if meals aren't adjusted deliberately, often means less protein too, not just fewer calories overall.
One of the more striking findings from the 2026 scoping review: out of 12 major GLP-1 clinical trials, only 3 included a registered dietitian or any structured nutrition support. Detailed data on what people were actually eating — protein intake, micronutrient status — was rarely collected in these trials at all.
Separate modeling research estimated that when food intake drops by 20–40%, as commonly happens on these medications, more than 90% of people may fall below recommended intake levels for vitamin D, with many also becoming inadequate in potassium, fiber, and other nutrients unless their diet is proactively adjusted to compensate for eating less overall food volume. Other commonly flagged nutrients of concern include protein, iron, vitamin B12, folate, and thiamine.
The takeaway here isn't that GLP-1 medications are nutritionally dangerous — it's that eating meaningfully less food, for any reason, requires more intentional attention to what you're eating, not just how much, and that this specific support has been inconsistently built into GLP-1 treatment programs so far.
Clinical guidance published in 2025 specifically addressing nutrition during GLP-1 treatment recommends a daily protein intake of at least 1.2 grams per kilogram of body weight, with up to 1.6 g/kg suggested for appropriate adults without advanced kidney disease. The same guidance suggests spreading protein across meals — targeting roughly 0.3 to 0.4 grams per kilogram at each eating occasion — since muscle protein synthesis responds better to protein spread throughout the day than to one large serving.
The same clinical guidance emphasizes progressive resistance training — generally described as 2 to 3 sessions per week targeting major muscle groups — as a key strategy for preserving lean mass and physical function during GLP-1-driven weight loss. Reviews on this topic frame the combination of adequate protein and resistance training as the difference between "weight loss" in the general sense and "fat-focused loss" that spares muscle as much as possible.
Specialist guidance also cautions against pushing food intake extremely low on top of the medication's own appetite-suppressing effect — sometimes described as maintaining an "energy floor" rather than compounding the medication's effect with additional restriction. Since GLP-1 medications already reduce hunger substantially, deliberately eating even less on top of that effect increases the risk of inadequate protein and micronutrient intake without providing additional benefit.
For people at higher risk — older adults, or anyone with pre-existing low muscle mass or frailty — some specialists recommend body composition monitoring (through methods like DXA scans or bioimpedance) to track the fat-to-muscle ratio of weight being lost, rather than relying on scale weight alone. Screening for micronutrient deficiencies is also sometimes recommended when intake has dropped significantly or when symptoms suggest a possible deficiency.
Some newer medications in development are specifically being evaluated with body composition in mind. CagriSema — a combination of semaglutide with cagrilintide, an appetite-reducing hormone analogue — has shown promising results in this area: in a body-composition substudy of its phase 3 trial, roughly two-thirds of the weight lost was fat mass, with the proportion of lean tissue relative to total body mass actually improving despite some absolute lean mass reduction. This suggests some newer combination therapies may produce a more fat-focused weight loss profile, though this is still early data, and long-term evidence specifically on lean mass preservation remains limited.
If you're on, or considering, a GLP-1 medication, this isn't a reason for alarm — it's a reason to build a plan around it. The research consistently points to the same two levers: getting enough protein, spread across your meals, and doing some form of regular resistance exercise. These aren't extreme measures — they're the same basic recommendations that apply to healthy weight loss generally, just with more evidence now specifically confirming why they matter alongside these medications.
If you're managing pre-existing health conditions, are significantly older, or have concerns about your muscle mass or strength going into treatment, this is worth raising directly with your prescriber — ideally before starting treatment, so a nutrition and activity plan can be built in from the beginning rather than added after concerns show up.
Q: Does this mean GLP-1 medications are bad for muscle health?
Not inherently — lean mass loss happens with most significant weight loss, not just GLP-1 medications. The research suggests it can be minimized with adequate protein and resistance exercise, which is true regardless of how the weight loss is achieved.
Q: How much protein do I actually need?
Clinical guidance suggests at least 1.2 grams per kilogram of body weight daily, up to 1.6 g/kg for some adults — though this should be discussed with your provider, particularly if you have any kidney conditions, since protein recommendations can differ in that case.
Q: Do I need to lift weights specifically, or does any exercise help?
The research specifically points to resistance training (strength training) as the most effective tool for preserving muscle during weight loss, generally described as 2–3 sessions per week. Aerobic exercise has its own health benefits but doesn't provide the same muscle-preserving stimulus.
Q: Is muscle loss reason enough to avoid these medications?
That's a personal and medical decision, not one this article can make for you — but the research suggests the issue is manageable with the right nutrition and exercise approach rather than being an unavoidable consequence of treatment.
Q: How would I know if I'm losing more muscle than expected?
Unexplained weakness, reduced physical function, or unusually fast strength loss are worth raising with a provider. Body composition testing (DXA or bioimpedance) is the more precise way to actually measure the fat-to-muscle ratio of weight lost, if that's a specific concern.
See also: GLP-1 Side Effects for a broader look at what to expect on these medications, including GI symptoms and serious but uncommon risks, and What Happens If You Stop Taking GLP-1 Medications? for how both weight and muscle composition respond to discontinuation.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizA clear look at GLP-1 side effects — from common nausea to rare but serious risks — based on FDA labeling and adverse event data, plus what tends to help.
GLP-1 medications start affecting appetite within days, but meaningful weight loss builds over months. Here's the actual week-by-week timeline from clinical trial data.
Research on stopping GLP-1 medications shows most people regain a significant share of lost weight. Here's what the data actually shows and why it happens.